SCHEMBL2934359

SCHEMBL2934359

CC(=O)C1C=Nc2ccccc2C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
POLB P06746 2/20 0.40
ALOX12 P18054 2/20 0.40
RECQL P46063 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
APAF1 O14727 1/20 0.40
TDP2 O95551 1/20 0.40
NSD2 O96028 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
HBB P68871 2/20 0.37
HSD17B10 Q99714 1/20 0.37
GLRA3 O75311 2/20 0.35
S100A4 P26447 2/20 0.35
NOTUM Q6P988 1/20 0.35
NFKB1 P19838 1/20 0.35
STAT3 P40763 1/20 0.35
STAT1 P42224 1/20 0.35
NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1444909 0.86 MAPT (0.38) MAPTALDH1A1POLBALOX12RECQL
SCHEMBL1450636 0.84 GABRP (0.34) MAPTALDH1A1POLBALOX12RECQL
Hydrochloric Acid SCHEMBL27338358 0.84 MAPT (0.37) MAPTALDH1A1POLBALOX12RECQL
SCHEMBL28846735 0.80 GABRP (0.35) MAPTALDH1A1HBBHSD17B10GLRA3
SCHEMBL4768344 0.80 KDM4E (0.42) MAPTALDH1A1L3MBTL1HSD17B10RAB9A
SCHEMBL2933046 0.76 GABRP (0.37) MAPTALDH1A1POLBALOX12RECQL
SCHEMBL13594533 0.76 ACHE (0.37) MAPTALDH1A1POLBL3MBTL1HBB
SCHEMBL9615419 0.75 NPSR1 (0.44) MAPTALDH1A1HSD17B10LMNASMN1; SMN2
SCHEMBL10372679 0.74 POLB (0.40) MAPTALDH1A1POLBALOX12RECQL
SCHEMBL18577748 0.73 PTPRC (0.47) MAPTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730135-B1 QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) US OF AMERICA REPRESENTED BY T (US) 2010-09-22 EP disclosed
US-7776883-B2 Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC) THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2010-08-17 US disclosed
US-20070219242-A1 Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE 2007-09-20 US disclosed
EP-1730135-A1 QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) The United States of America, represented by the Secretary, Department of Health and Human Services (US) 2006-12-13 EP disclosed
WO-2005087759-A1 QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219242-A1 Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) QTRT1, QTRT2, CTCF MAPT 1583/4885ALDH1A1 2320/4885POLB 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.